J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

 
• By Mandy Jackson
  
3d illustration of T cells or cancer cells
Myeloma patients have responded well to T-cells engineered to target BCMA. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas